Orchid Pharma valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
482.91×————
3.31×————
4.83×————
Enterprise multiples
5.10×————
123.72×————
1,226.00×————
Yield
0.2%————
−5.1%————
Reference — adjusted share basis
₹865.00————
₹1.79₹1.66₹16.64₹15.39₹7.73
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ORCHPHARMA₹865.00

Orchid Pharma Limited

· Pharma & Health
₹ CrorePeersFDCGUJTHEMIOLCPMOREPENLABRPGLIFEGUFICBIOINNOVACAPUNICHEMLABMcap ₹5,180 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————482.91
P/B————3.31
P/Sales————4.83
Enterprise Multiples
EV/Sales————5.10
EV/EBITDA————123.72
EV/EBIT————1,226.00
Yield
Earnings Yield %————0.21
FCF Yield %————-5.10
Reference — adjusted share basis
Price (FY-end close, adj.)————865.00
EPS (adj.)7.7315.3916.641.661.79
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.